Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

reatening problems."

The sickle cell trial grew out of research by Dr. Linden, who is a leading expert on adenosine receptors, which are known to act as a natural brake on inflammation. While Dr. Linden had previously explored adenosine's role in protecting tissues from damage due to low blood flow in single tissues such as in heart disease, he was struck one day with the idea that it might also protect people with sickle cell disease, who suffer tissue damage from poor blood flow to most tissues.

Dr. Linden began testing his theory in mouse models about four years ago and found that adenosine-like compounds significantly reduced the damaging effects of the disease. He was aware of an existing FDA approved adenosine-like drug, Lexiscan that had already been approved for another use. "This was good news since it meant that Lexiscan was known to be safe in humans and could probably gain rapid approval if proven effective in clinical trials as a treatment for sickle cell disease," he said.

Dr. Linden joined forces with Dr. Nathan, who participated in the development of the only existing FDA-approved drug for sickle cell treatment, hydroxyurea, and another clinical collaborator, Dr. Field, to seek NIH funding for the Lexiscan trial. They launched the trial's first phase in 2010 using patient volunteers from Brigham and Women's Hospital in Boston and Washington University in St. Louis.

In the trial, Dr. Nathan, Dr. Field and other clinicians collected blood from patients and sent it to Dr. Linden in La Jolla for analysis of white blood cell inflammation. Gene Lin, Ph.D., a scientist in Linden's lab, has been a significant contributor to the analysis effort. The same protocol will be used in the trial's second phase.

Lexiscan is approved as a pharmacologic stress agent used for myocardial perfusion imaging (MPI), a procedure that measures coronary blood flow to help in the diagnosis of heart disease. Lexiscan is u
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... With only two weeks to go and almost a ... 2013 have reached their final stages. This year,s conference ... Simons will deliver the opening keynote lecture and explain ... cells work. In further keynote lectures, Hans Clevers will ...
... 9, 2013 Cytos Biotechnology Ltd (SIX:CYTN) today ... CYT003, a first-in-class immune modulator in clinical development as a ... data published in the March issue of The Journal ... at the European Respiratory Society Annual Congress in ...
... 2013 Disease-causing bacteria stink literally and the ... the basis for a faster and simpler new way to ... here today at the 246th National Meeting & Exposition of ... The new test produces results in 24 hours, compared ...
Cached Biology News:All set for The EMBO Meeting 2013 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 4Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 5New 'artificial nose' device can speed diagnosis of sepsis 2
(Date:11/27/2014)... -- Research and Markets  has announced ... Report 2014" report to their offering. ... Palmitic Acid Industry Report 2014 is a professional and ... palmitic acid industry. The report provides a ... and industry chain structure. The palmitic acid market analysis ...
(Date:11/26/2014)... 21, 2014 (PRWEB) November 26, 2014 ... communications network, today announced the organization has won a ... Club Awards. Digitas Health LifeBrands was honored with a ... other PHCG agencies received eight Awards of Excellence. ... aspects of pharmaceutical advertising and promotion. The Awards provide ...
(Date:11/26/2014)... The announced sales of three healthcare units ... to expand in non-healthcare areas, says Kalorama Information. Siemens ... firm says that  Siemens is the third largest company ... the IVD market , with 5.5 billion in IVD ... would likely affect IVD market shares.  ...
(Date:11/26/2014)... PMG Research, Inc. announced today the ... network of sites that provide clinical research services to pharmaceutical ... lives through its partnerships with large physician practices and integrated ... locations in the Southeastern United States and spans over 60 ... board will be held by: Dr. Robert Holmes, MD, ...
Breaking Biology Technology:Global Palmitic Acid Industry Report 2014 2Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3
... ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 27 PDL BioPharma, Inc. (PDL, ... it has entered into separate privately negotiated exchange agreements under ... the Company,s outstanding 2.00% Convertible Senior Notes due February 15, ... holders of the 2012 Notes will receive $92.0 million in ...
Cached Biology Technology:Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 2Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 3Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 4Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 5Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 6Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 7Enerkem Successfully Meets Federal Environmental Assessment Requirements for its Mississippi Waste-to-Ethanol Plant 8The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 2PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 3
EML1 (K-16)...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Biology Products: